JP2021529172A5 - - Google Patents
Info
- Publication number
- JP2021529172A5 JP2021529172A5 JP2020570902A JP2020570902A JP2021529172A5 JP 2021529172 A5 JP2021529172 A5 JP 2021529172A5 JP 2020570902 A JP2020570902 A JP 2020570902A JP 2020570902 A JP2020570902 A JP 2020570902A JP 2021529172 A5 JP2021529172 A5 JP 2021529172A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- prodrug
- alkyl
- compound according
- Prior art date
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688225P | 2018-06-21 | 2018-06-21 | |
| US62/688,225 | 2018-06-21 | ||
| US201962827505P | 2019-04-01 | 2019-04-01 | |
| US62/827,505 | 2019-04-01 | ||
| PCT/US2019/038245 WO2019246403A1 (en) | 2018-06-21 | 2019-06-20 | Ectonucleotidase inhibitors and methods of use thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021529172A JP2021529172A (ja) | 2021-10-28 |
| JPWO2019246403A5 JPWO2019246403A5 (https=) | 2022-05-16 |
| JP2021529172A5 true JP2021529172A5 (https=) | 2022-05-16 |
| JP7538047B2 JP7538047B2 (ja) | 2024-08-21 |
Family
ID=68981317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570902A Active JP7538047B2 (ja) | 2018-06-21 | 2019-06-20 | エクトヌクレオチダーゼ阻害剤及びその使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11078228B2 (https=) |
| EP (1) | EP3810617A4 (https=) |
| JP (1) | JP7538047B2 (https=) |
| KR (1) | KR102902754B1 (https=) |
| CN (1) | CN112888696B (https=) |
| AU (1) | AU2019288495B2 (https=) |
| BR (1) | BR112020025132B1 (https=) |
| CA (1) | CA3104088A1 (https=) |
| CL (1) | CL2020003339A1 (https=) |
| CO (1) | CO2021000049A2 (https=) |
| IL (1) | IL279475B2 (https=) |
| MX (1) | MX2020013320A (https=) |
| PH (1) | PH12020552214A1 (https=) |
| SG (1) | SG11202012001YA (https=) |
| TW (1) | TWI911140B (https=) |
| WO (1) | WO2019246403A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7138351B2 (ja) * | 2016-12-22 | 2022-09-16 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | エクトヌクレオチダーゼ阻害剤およびその使用方法 |
| WO2018208980A1 (en) | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CN112423764A (zh) | 2018-04-30 | 2021-02-26 | 欧瑞克制药公司 | Cd73抑制剂 |
| AU2019288495B2 (en) | 2018-06-21 | 2024-02-08 | Antengene Therapeutics Limited | Ectonucleotidase inhibitors and methods of use thereof |
| TWI821559B (zh) * | 2019-04-28 | 2023-11-11 | 大陸商上海和譽生物醫藥科技有限公司 | 一種cd73抑制劑，其製備方法和應用 |
| KR20220024629A (ko) * | 2019-06-20 | 2022-03-03 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 엑토뉴클레오티다제 억제제 및 이의 사용 방법 |
| US12544391B2 (en) | 2019-07-16 | 2026-02-10 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| HUE072504T2 (hu) | 2019-10-30 | 2025-11-28 | Oric Pharmaceuticals Inc | CD73-inhibitorok |
| CN119173276A (zh) | 2022-04-13 | 2024-12-20 | 吉利德科学公司 | 用于治疗表达Trop-2的癌症的组合疗法 |
| CN115873049B (zh) * | 2023-02-13 | 2023-05-02 | 北京先通国际医药科技股份有限公司 | 腺苷的制备方法及其用途 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2085994A1 (en) | 1991-04-24 | 1992-10-25 | Shinji Sakata | 1-beta-d-arabinofuranosyl-(e)-5- (2-halogenovinyl) uracil derivatives |
| AU5449094A (en) | 1992-11-02 | 1994-05-24 | Affymax Technologies N.V. | Novel photoreactive protecting groups |
| US5635608A (en) | 1994-11-08 | 1997-06-03 | Molecular Probes, Inc. | α-carboxy caged compounds |
| TW528755B (en) | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
| NL1005244C2 (nl) | 1997-02-10 | 1998-08-18 | Inst Voor Agrotech Onderzoek | Oppervlakte-actieve aminen en glycosiden. |
| WO2004096233A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates |
| EP1860113A1 (en) | 2006-05-24 | 2007-11-28 | Rheinische Friedrich-Wilhelms-Universität Bonn | Ectonucleotidase inhibitors |
| WO2008011406A2 (en) * | 2006-07-18 | 2008-01-24 | Anadys Pharmaceuticals, Inc. | Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines |
| JP2011503084A (ja) | 2007-11-07 | 2011-01-27 | シェーリング コーポレイション | 新規の細胞周期チェックポイント調節剤およびこれらの調節剤とチェックポイント阻害剤との併用 |
| EP2070938A1 (en) * | 2007-12-13 | 2009-06-17 | Heidelberg Pharma AG | Clofarabine dietherphospholipid derivatives |
| CA2684017A1 (en) | 2009-10-22 | 2011-04-22 | Universite Laval | Ectonucleotidase pyrophosphate/phosphodiesterase-1 (enpp-1) as a target for the treatment of aortic valve stenosis and cardiovascular calcification |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| EP2590958B1 (en) | 2010-07-08 | 2015-08-26 | Life Technologies Corporation | In situ chemiluminescent substrates and assays |
| CN102311472B (zh) | 2010-07-09 | 2014-09-03 | 神隆(昆山)生化科技有限公司 | 2-氯-9-(2’-脱氧-2’-氟-β-D-阿拉伯呋喃糖基)-腺嘌呤的制备 |
| US20140154675A1 (en) | 2011-05-03 | 2014-06-05 | Life Technologies Corporation | Flash and Glow 1,2-Dioxetanes |
| DK2731947T3 (en) * | 2011-07-15 | 2019-04-23 | Boehringer Ingelheim Int | SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES |
| GB201220843D0 (en) | 2012-11-20 | 2013-01-02 | Univ College Cork Nat Univ Ie | Compound |
| US10068577B2 (en) * | 2014-04-25 | 2018-09-04 | Dolby Laboratories Licensing Corporation | Audio segmentation based on spatial metadata |
| WO2015164573A1 (en) * | 2014-04-25 | 2015-10-29 | Vitae Pharmaceuticals, Inc. | Purine derivatives as cd73 inhibitors for the treatment of cancer |
| WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
| WO2017066781A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified phosphate linkage |
| WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
| US10611790B2 (en) | 2015-11-02 | 2020-04-07 | Mitobridge, Inc. | Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases |
| TWI704154B (zh) * | 2015-12-03 | 2020-09-11 | 英商葛蘭素史克智慧財產發展有限公司 | 新穎化合物 |
| TWI767937B (zh) * | 2016-09-09 | 2022-06-21 | 美商卡利泰拉生物科技公司 | 外核苷酸酶抑制劑及其使用方法 |
| US10794113B2 (en) * | 2016-12-22 | 2020-10-06 | Marketing Displays, Inc. | Compact privacy screen |
| JP7138351B2 (ja) | 2016-12-22 | 2022-09-16 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | エクトヌクレオチダーゼ阻害剤およびその使用方法 |
| WO2018208727A1 (en) * | 2017-05-08 | 2018-11-15 | Eternity Bioscience Inc. | Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof |
| WO2018208980A1 (en) * | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| CN109503587B (zh) * | 2017-09-14 | 2022-01-11 | 辽宁利锋科技开发有限公司 | 双杂环三氮唑核苷类似物的抗肿瘤作用与应用 |
| US11377469B2 (en) * | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CN112423764A (zh) * | 2018-04-30 | 2021-02-26 | 欧瑞克制药公司 | Cd73抑制剂 |
| EP3810109B1 (en) * | 2018-05-31 | 2024-08-07 | Peloton Therapeutics, Inc. | Compounds and compositions for inhibiting cd73 |
| AU2019288495B2 (en) | 2018-06-21 | 2024-02-08 | Antengene Therapeutics Limited | Ectonucleotidase inhibitors and methods of use thereof |
| KR20220024629A (ko) | 2019-06-20 | 2022-03-03 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 엑토뉴클레오티다제 억제제 및 이의 사용 방법 |
-
2019
- 2019-06-20 AU AU2019288495A patent/AU2019288495B2/en active Active
- 2019-06-20 MX MX2020013320A patent/MX2020013320A/es unknown
- 2019-06-20 CN CN201980054369.1A patent/CN112888696B/zh active Active
- 2019-06-20 SG SG11202012001YA patent/SG11202012001YA/en unknown
- 2019-06-20 US US16/447,159 patent/US11078228B2/en active Active
- 2019-06-20 EP EP19823042.7A patent/EP3810617A4/en active Pending
- 2019-06-20 JP JP2020570902A patent/JP7538047B2/ja active Active
- 2019-06-20 KR KR1020217001701A patent/KR102902754B1/ko active Active
- 2019-06-20 CA CA3104088A patent/CA3104088A1/en active Pending
- 2019-06-20 BR BR112020025132-1A patent/BR112020025132B1/pt active IP Right Grant
- 2019-06-20 WO PCT/US2019/038245 patent/WO2019246403A1/en not_active Ceased
- 2019-06-20 IL IL279475A patent/IL279475B2/en unknown
- 2019-06-21 TW TW108121817A patent/TWI911140B/zh active
-
2020
- 2020-12-18 PH PH12020552214A patent/PH12020552214A1/en unknown
- 2020-12-21 CL CL2020003339A patent/CL2020003339A1/es unknown
-
2021
- 2021-01-06 CO CONC2021/0000049A patent/CO2021000049A2/es unknown
- 2021-06-28 US US17/359,990 patent/US11858957B2/en active Active
-
2023
- 2023-11-01 US US18/499,248 patent/US12421273B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021529172A5 (https=) | ||
| JP6523303B2 (ja) | Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物 | |
| AU2015207757B2 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | |
| HRP20210848T1 (hr) | Sastavi i postupci za sprječavanje aktivnosti arginaze | |
| JP2019530669A5 (https=) | ||
| WO2018051254A1 (en) | Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators | |
| WO2018051255A1 (en) | Cyclic substituted-1,3,4-oxadiazole and thiadiazole compounds as immunomodulators | |
| JP2020504735A5 (https=) | ||
| JP2017515802A5 (https=) | ||
| JP2016502544A5 (https=) | ||
| JP2019524852A5 (https=) | ||
| RU2015116102A (ru) | Гетероароматические соединения-модуляторы фосфоинозидит-3-киназы и способы применения | |
| CA2992960A1 (en) | Fused imidazoles as midh1 inhibitors | |
| JP2018529780A5 (https=) | ||
| CA2992364A1 (en) | 5-hydroxyalkylbenzimidazoles as midh1 inhibitors | |
| JP2015536994A5 (https=) | ||
| CA2996681C (en) | Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy | |
| RU2015131467A (ru) | Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы | |
| CA2988356A1 (en) | N-menthylbenzimidazoles as midh1 inhibitors | |
| JP2017502967A5 (https=) | ||
| CA2965201A1 (en) | Benzimidazol-2-amines as midh1 inhibitors | |
| CN111836621A (zh) | 使用1,2,4-噁二唑化合物调节tigit和pd-1信号传导途径的方法 | |
| WO2016202758A1 (en) | Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds | |
| JPWO2019246403A5 (https=) | ||
| WO2018054989A4 (en) | Benzoimidazole derivatives as anticancer agents |